{"url_path":"/sec/otlk/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-062632-index.html","accession_number":"0001104659-26-062632","cik":"0001649989","ticker":"OTLK","issuer_name":"Outlook Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-062632-index.html","primary_entity_key":"0001649989","primary_entity_name":"Outlook Therapeutics, Inc."},"word_count":413,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n​\n\n​\n\n​\n\n​\n\n**Exhibit Number**\n\n**Description**\n\n3.1\n\n[Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024).](https://www.sec.gov/Archives/edgar/data/1649989/000155837024008318/otlk-20240331xex3d1.htm)\n\n​\n\n​\n\n3.2\n\n[Certificate of Amendment of the Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s current report on Form 8-K filed with the SEC on March 14, 2025)](https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/otlk-20250311xex3d1.htm)\n\n​\n\n​\n\n3.3\n\n[Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s current report on Form 8-K filed with the SEC on March 26, 2021).](https://www.sec.gov/Archives/edgar/data/1649989/000110465921042442/tm2110800d1_ex3-2.htm)\n\n​\n\n​\n\n31.1\n\n[Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.](otlk-20260331xex31d1.htm)\n\n​\n\n​\n\n31.2\n\n[Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.](otlk-20260331xex31d2.htm)\n\n​\n\n​\n\n32.1*\n\n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](otlk-20260331xex32d1.htm)\n\n​\n\n​\n\n32.2*\n\n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](otlk-20260331xex32d2.htm)\n\n​\n\n​\n\n101.INS**\n\nInline XBRL Instance Document.\n\n​\n\n​\n\n101.SCH***\n\nInline XBRL Taxonomy Extension Schema Document.\n\n​\n\n​\n\n101.CAL***\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document.\n\n​\n\n​\n\n101.DEF***\n\nInline XBRL Definition Linkbase Document.\n\n​\n\n​\n\n101.LAB***\n\nInline XBRL Taxonomy Extension Labels Linkbase Document.\n\n​\n\n​\n\n101.PRE***\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document.\n\n​\n\n​\n\n104**\n\nCover Page Interactive Data File.\n\n*\n\nFurnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.\n\n**\n\nThe XBRL Instance Document and Cover Page Interactive Data File do not appear in the Interactive Data File because their XBRL tags are embedded within the Inline XBRL document.\n\n***\n\nSubmitted electronically with the report.\n\n​\n\n43\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n**OUTLOOK THERAPEUTICS, INC.**\n\n​\n\n​\n\n​\n\nDate: May 15, 2026\n\nBy:\n\n/s/ Lawrence A. Kenyon\n\nLawrence A. Kenyon\n\nChief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n​\n\n​\n\n44"}